Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ICML 2019 | CLL treatment for the old and young

Matthew Davids • 20 Jun 2019
ICML 2019
Chronic Lymphocytic Leukemia Leukemia Lymphoma Ibrutinib Venetoclax

Chronic lymphocytic leukemia (CLL) treatment is different for the young and old. The treatment approaches are discussed here by Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

More from Matthew Davids

Targeted therapies that appear likely to impact CLL practice in the coming years
1:51
Targeted therapies that appear likely to impact CLL practice in the coming years
Matthew Davids • 8 Dec 2025
Developing and testing a tandem CD19/ROR1 CAR-NK to overcome apoptotic resistance in CLL
1:21
Developing and testing a tandem CD19/ROR1 CAR-NK to overcome apoptotic resistance in CLL
Matthew Davids • 8 Dec 2025
Fixed-duration and MRD-adapted therapy in CLL: insights from ASH 2025
2:08
Fixed-duration and MRD-adapted therapy in CLL: insights from ASH 2025
Matthew Davids • 8 Dec 2025
Mutation-guided finite-duration AV after first-line BTKi+ven-based therapy in CLL/SLL: MAVRiC trial
1:27
Mutation-guided finite-duration AV after first-line BTKi+ven-based therapy in CLL/SLL: MAVRiC trial
Matthew Davids • 8 Dec 2025

Related Videos

cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
1:10
cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
Matthew Davids • 24 Nov 2025
Single-agent SC blinatumomab in R/R B-ALL: Phase I/II efficacy results with extended follow-up
1:16
Single-agent SC blinatumomab in R/R B-ALL: Phase I/II efficacy results with extended follow-up
Matthew Davids • 24 Nov 2025
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Matthew Davids • 6 Dec 2025
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
2:20
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
Matthew Davids • 6 Dec 2025
The content of VJHemOnc is intended for healthcare professionals